Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p
The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a